Mankind Pharma Ltd Share Price – NSE  / BSE

Pharmaceuticals, Mid Cap

Mankind Pharma Ltd is up for a fifth straight session in a row. The stock is quoting at Rs 2301.2, up 2.96% on the day as on 12:44 IST on the NSE. The benchmark NIFTY is down around 0.72% on the day, quoting at 24201.65. The Sensex is at 77776.44, down 0.94%. Mankind Pharma Ltd has added around 15.77% in last one month.

Meanwhile, Nifty Pharma index of which Mankind Pharma Ltd is a constituent, has added around 3.23% in last one month and is currently quoting at 22455.45, up 2.24% on the day. The volume in the stock stood at 7.66 lakh shares today, compared to the daily average of 5.37 lakh shares in last one month.

The benchmark April futures contract for the stock is quoting at Rs 2290.5, up 2.77% on the day. Mankind Pharma Ltd is down 11.47% in last one year as compared to a 0.19% fall in NIFTY and a 4.48% fall in the Nifty Pharma index.

The PE of the stock is 52.22 based on TTM earnings ending December 25.

Mankind Pharma Ltd is up for a third straight session today. The stock is quoting at Rs 2188.2, up 2.06% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is up around 0.72% on the day, quoting at 24539.15. The Sensex is at 79191.47, up 0.85%. Mankind Pharma Ltd has gained around 13.53% in last one month.

Meanwhile, Nifty Pharma index of which Mankind Pharma Ltd is a constituent, has gained around 1.89% in last one month and is currently quoting at 22456.75, up 0.06% on the day. The volume in the stock stood at 1.76 lakh shares today, compared to the daily average of 5.54 lakh shares in last one month.

The benchmark April futures contract for the stock is quoting at Rs 2178.8, up 1.87% on the day. Mankind Pharma Ltd is down 15.17% in last one year as compared to a 1.54% jump in NIFTY and a 4.82% jump in the Nifty Pharma index.

The PE of the stock is 50.08 based on TTM earnings ending December 25.

The board of Mankind Pharma at its meeting held on 13 April 2026 has approved the closure/winding-up of Mankind Pharma Lanka, a wholly owned subsidiary (WOS) company incorporated in Sri Lanka, as due to changed regulatory requirements, the anticipated business objectives are no longer viable.

There has been no business operations in the aforesaid WOS, and it is not a material subsidiary of the Company.

Rivotril, the innovator/reference brand of clonazepam, is widely prescribed for the management of neurological and psychiatric conditions. Known as a textbook brand with a strong clinical legacy, the acquisition reinforces Mankind Pharma?s presence in the central nervous system (CNS) therapy segment and complements its existing neuro portfolio.

The move aligns with Mankind Pharma?s growing focus on chronic therapies, an area where the company has expanded steadily through new product launches, in-licensing partnerships, and portfolio additions across key therapeutic areas. Chronic therapies now contribute an increasing share to the company?s overall business, enabling deeper engagement with specialists and key opinion leaders.

Atish Majumdar, senior president, sales & marketing, Mankind Pharma Specialty Business, said, ?This acquisition is aligned with our strategic focus on strengthening our presence in chronic and specialty therapies. We see strong opportunities to build on this platform through potential line extensions, addressing the evolving needs of patients and physicians in the CNS therapy area. Leveraging our large field force and nationwide distribution network, we are well positioned to build the brand and support physicians in delivering better outcomes for patients across India.?

Mankind Pharma plans to utilize its extensive distribution network and field force to expand access to Rivotril across healthcare institutions and prescribers. The company currently engages with over 5 lakh doctors in India, enabling strong prescription penetration across urban and semi-urban markets.

Mankind Pharma is one of India?s largest pharmaceutical companies, operating with a pan-India presence. The company manufactures a wide range of dosage forms, including tablets, capsules, syrups, vials, ampoules, blow-fill-seal products, soft and hard gels, eye drops, creams, contraceptives, and other over-the-counter products across 32 manufacturing facilities. It also maintains six dedicated R&D centers with more than 730 scientists, supporting a consistent track record of product innovation.

The company reported a 7.5% rise in consolidated net profit of Rs 408.75 crore in Q3 FY26 as against Rs 380.23 crore posted in Q3 FY25. Net sales fell 11.5% YoY to Rs 3,567.20 crore in the quarter ended 31 December 2025.

Powered by Capital Market - Live News